Monoclonal antibodies against IL-1β (e.g., canakinumab) or TNF-α (e.g., infliximab, etanercept), already in clinical use for rheumatoid arthritis and other inflammatory diseases, hold theoretical potential for controlling periodontal inflammation. Here, TNF is linked to rheumatoid arthritis.